Long-term oral azithromycin in chronic plaque psoriasis: A controlled trial

European Journal of Dermatology

Volumn 20, Issue 3, 2010, Pages 329-333

  Saxena, V N ^a   Dogra, Jaideep ^b  

^a SMS MEDICAL COLLEGE   (India)

^b CGHS Jaipur (India)   (India)

Author keywords

Chronic plaque psoriasis; Long term azithromycin; Streptococci

Indexed keywords

ASCORBIC ACID; AZITHROMYCIN;

ABDOMINAL DISCOMFORT; ADOLESCENT; ADULT; ARTICLE; CHRONIC DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG TOLERABILITY; FEMALE; FOLLOW UP; HUMAN; INFORMED CONSENT; LONG TERM CARE; MALE; NAUSEA; PATIENT SATISFACTION; PSORIASIS VULGARIS; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; RELAPSE; SINGLE BLIND PROCEDURE; SINGLE DRUG DOSE; TREATMENT DURATION; TREATMENT RESPONSE;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; ANTI-BACTERIAL AGENTS; AZITHROMYCIN; CHRONIC DISEASE; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PSORIASIS; RECURRENCE; REMISSION INDUCTION; SEVERITY OF ILLNESS INDEX; SINGLE-BLIND METHOD; SKIN; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 77952833392     PISSN: 11671122     EISSN: 19524013     Source Type: Journal    
DOI: 10.1684/ejd.2010.0930     Document Type: Article

References (22)

1. Barker J. Skin diseases with high public health impact. Psoriasis. Eur J Dermatol 2007; 17: 563-564
2. Balci DD, Duran N, Ozer B, Gunessacar R, Onlen Y, Yenin JZ. High prevalence of Staphylococcus aureus cultivation and superantigen production in patients with psoriasis. Eur J Dermatol 2009; 19: 238-242
3. Valdimarsson H, Sigmundsdottir H, Jonsdottir I. Is psoriasis induced by streptococcal super antigens and maintained by M- protein specific T cells that cross react with keratin? Clin Exp Immunol 1997; 107: 21-24
4. Prinz JC. Psoriasis vulgaris- a sterile anti-bacterial skin reaction mediated by cross reactive T cells? An immunological view of the patho physiology of psoriasis. Clin Exp Dermatol 2001; 26: 326-332 (Pubitemid 34204346)
5. Olivier C. Rheumatic fever- is it still a problem? J Antimicrob Chemother 2000; 45: 13-21.
6. Saxena VN, Dogra J. Long term use of penicillin for the treatment of chronic plaque psoriasis. Eur J Dermatol 2005; 15: 359-362 (Pubitemid 41337413)
7. Walter J, Seeney S, Bell S, Bowler S, Masel T, McCormack J. Effect of long term treatment with azithromycin on disease parameters in cystic fibrosis: a randomised trial. Thorax 2002; 57: 212-216 (Pubitemid 34214405)
8. Saiman L, Marshall BC, Mayer-Hamblett N, et al. Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA 2003; 290: 1749-1756 (Pubitemid 37430625)
9. Havlir DV, Dube MP, Sattler FR, et al. Prophylaxis against disseminated Mycobacterium avium Complex with weekly azithromycin, daily rifabutum or both. NEJM 1996; 335: 392-398
10. Gruber F, Grubisic-Greblo H, Kastelan M, Brajac I, Lenkovic M. Azithromycin compared with minocycline in the treatment of acne comedeonica and papulo - pustulasa. J Chemother 1998; 10: 469-473 (Pubitemid 128506705)
11. Newell DJ. Intention-to-treat analysis: implications for quantitative and qualitative research. Int J Epidemiol 1992; 21: 837-847
12. Baker BS, Swain AF, Fry L, Valdimarsson H. Epidermal T lymphocytes and HLA-DR expression in psoriasis. Br J Dermatol 1984; 11: 555-564 (Pubitemid 14146263)
13. Ohshima A, Takigawa M, Tokura Y. CD 8 + Cell changes in psoriasis associated with Roxithromycin-induced clinical improvement. Eur J Dermatol 2001; 11: 410-415 (Pubitemid 32801335)
14. Konno S, Adachi M, Asano K, Okamoto K. Inhibition of human T lymphocyte activation by macrolide antibiotic, Roxithromycin. Life Sci 1992; 51: 231-236
15. Wakita H, Tokura Y, Furukawa F, Takigawa M. The macrolide antibiotic, Roxithromycin suppress IFN-gamma mediated immunological functions of cultured normal human keratinocytes. Biol Pharm Bull 1996; 19: 224-227
16. Fredriksson T, Pettersson U. Severe psoriasis: oral therapy with a new retionoid. Dermatologica 1978; 157: 238-244 (Pubitemid 8387357)
17. Naldi L. Scoring and monitoring the severity of psoriasis. What is the preferred method? What is the ideal method? Is PASI passé? Facts and controversies. Clinics in Dermatology 2010; 28: 67-72.
18. Greiner RA, Braathen LR. Cost-effectiveness of biologics for moderate-to-severe psoriasis from the perspective of the Swiss healthcare system. Eur J Dermatol 2009; 19: 494-499
19. Krueger GG, Feldman SR, Camisa C, et al. Two considerations for patients with psoriasis and their clinicians: what defines mild, moderate and severe psoriasis? What constitutes a clinically significant improvement when treating psoriasis? J Am Acad Dermatol 2000; 43: 281-285
20. Rapaport MJ. PASI 75. J Am Acad Dermatol 2005; 52: 183-184
21. Mcfadden JP, Baker BS, Powles AV, Fry L. Psoriasis and streptococci: the natural selection of psoriasis revisited. Br J Dermatol 2009; 1690: 929-937
22. EL-Rachkidy RG. Hales JM, Freestone PPE, Young HS, Griffiths EM, Camp RDR. Increased blood levels of IgG reactive with secreted streptococcus pyogenes proteins in chronic plaque psoriasis. J Invest Dermatol 2007; 127: 1337-1342